{
    "nctId": "NCT05206656",
    "briefTitle": "Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer",
    "officialTitle": "Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer Patients: An Open-Labeled, Single-center, Prospective Study",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "Progression-Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years old, voluntary consent and signed written informed consent\n* ECOG 0\\~2\n* Pathologically diagnosed HER2-negative breast cancer patients with radiologically confirmed locally advanced (stage IIIB or IIIC) or metastatic (stage IV) breast cancer; HR-positive patients were permitted\n* At least one measurable disease lesion before treatment\n* Never receive Eribulin Mesylate treatment or anti-angiogenetic therapies before recruitment\n* Anticipated survival time is longer than three months\n* Brain metastases with stable disease or without clinical symptom\n* Blood routine test, liver and kidney function test meet the following criteria: PLT \\> 100g / L, Hb \\> 9g / L, Neutrophil \\> 2.0 g/L; AST and ALT \\< 2.5 upper limit of normal (ULN); Cr \\< 1.0 ULN; TBIL \\< 1.5ULN\n* Previously treated with anthracycline-based and taxane-based chemotherapy regimens (at least one line of chemotherapy in the metastatic setting or the recurrence time is less than 1 year from the end of adjuvant or neoadjuvant chemotherapy); for HR-positive/HER2-negative patients, progressed after at least one line of endocrine therapy\n* For women with fertility, the pregnancy test before administration was negative, and agreed to take appropriate measures to avoid pregnancy during the study treatment and at least half a year after the end of treatment; Men agreed to take appropriate contraceptive measures during the study treatment and at least half a year after the end of the treatment.\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Active infection requiring systemic treatment\n* HIV positive\n* Suffering from or suspected of suffering from central neuromuscular system diseases\n* Serious heart disease; uncontrollable hypertension; history of heavy hemorrhea\uff1brecent operation within three months\n* The investigator considered that the patient was not suitable for in this study, with any other situation.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}